DE60130675D1 - Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose - Google Patents

Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose

Info

Publication number
DE60130675D1
DE60130675D1 DE60130675T DE60130675T DE60130675D1 DE 60130675 D1 DE60130675 D1 DE 60130675D1 DE 60130675 T DE60130675 T DE 60130675T DE 60130675 T DE60130675 T DE 60130675T DE 60130675 D1 DE60130675 D1 DE 60130675D1
Authority
DE
Germany
Prior art keywords
osteoporosis
receptor
treatment
selective agonists
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60130675T
Other languages
English (en)
Other versions
DE60130675T2 (de
Inventor
Groton Cameron
Groton Lefker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60130675D1 publication Critical patent/DE60130675D1/de
Publication of DE60130675T2 publication Critical patent/DE60130675T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DE60130675T 2000-11-27 2001-11-05 Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose Expired - Fee Related DE60130675T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27
US253275P 2000-11-27
PCT/IB2001/002073 WO2002042268A2 (en) 2000-11-27 2001-11-05 Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (2)

Publication Number Publication Date
DE60130675D1 true DE60130675D1 (de) 2007-11-08
DE60130675T2 DE60130675T2 (de) 2008-01-24

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130675T Expired - Fee Related DE60130675T2 (de) 2000-11-27 2001-11-05 Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose

Country Status (41)

Country Link
US (3) US6552067B2 (de)
EP (1) EP1339678B1 (de)
JP (2) JP3984164B2 (de)
KR (1) KR20030053063A (de)
CN (1) CN1476429A (de)
AR (1) AR035074A1 (de)
AT (1) ATE374182T1 (de)
AU (1) AU2002210848A1 (de)
BG (1) BG107697A (de)
BR (1) BR0115687A (de)
CA (1) CA2429850C (de)
CY (1) CY1106976T1 (de)
CZ (1) CZ20031257A3 (de)
DE (1) DE60130675T2 (de)
DK (1) DK1339678T3 (de)
EA (1) EA200300379A1 (de)
EC (1) ECSP034623A (de)
EE (1) EE200300246A (de)
ES (1) ES2291361T3 (de)
GT (2) GT200100238AA (de)
HN (1) HN2001000266A (de)
HU (1) HUP0400807A2 (de)
IL (1) IL155368A0 (de)
IS (1) IS6775A (de)
MA (1) MA26961A1 (de)
MX (1) MXPA03004623A (de)
NO (1) NO20032360L (de)
NZ (1) NZ525164A (de)
OA (1) OA12533A (de)
PA (1) PA8533901A1 (de)
PE (1) PE20020637A1 (de)
PL (1) PL362030A1 (de)
PT (1) PT1339678E (de)
SI (1) SI1339678T1 (de)
SK (1) SK5562003A3 (de)
SV (1) SV2003000746A (de)
TN (1) TNSN01166A1 (de)
TW (1) TW200424170A (de)
UY (1) UY27038A1 (de)
WO (1) WO2002042268A2 (de)
ZA (1) ZA200302803B (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2429850C (en) * 2000-11-27 2008-12-30 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
KR20040015364A (ko) * 2001-07-16 2004-02-18 에프. 호프만-라 로슈 아게 Ep4 수용체 작용물질로서의 프로스타글란딘 유사체
BR0211167A (pt) * 2001-07-16 2004-08-10 Hoffmann La Roche Derivados de 2-pirrolidona como agonistas de prostanóides
MXPA04000757A (es) 2001-07-23 2004-07-08 Ono Pharmaceutical Co Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo.
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 8−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
JP2005531516A (ja) * 2002-03-18 2005-10-20 ファイザー・プロダクツ・インク 選択的ep4受容体アゴニストによる治療方法
WO2003077908A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
EP1513589B1 (de) 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
JP2005534653A (ja) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてep4受容体作動薬として使用するための1,5−二置換イミダゾリジン−2−オン誘導体
EP1556347A4 (de) * 2002-06-10 2006-08-09 Applied Research Systems Gamma-lactame als prostaglandinagonisten und deren verwendung
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
JP4497320B2 (ja) 2002-10-10 2010-07-07 小野薬品工業株式会社 内因性修復因子産生促進剤
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7528163B2 (en) 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (en) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
WO2004065365A1 (ja) * 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. 8−アザプロスタグランジン誘導体およびその医薬用途
JP4662926B2 (ja) 2003-03-03 2011-03-30 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγ−ラクタム誘導体
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
WO2005012232A2 (en) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
CN1845904A (zh) 2003-09-04 2006-10-11 默克公司 用于治疗高眼压的眼用组合物
JP2007504236A (ja) 2003-09-04 2007-03-01 メルク エンド カムパニー インコーポレーテッド 高眼圧症を治療するための眼用組成物
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
BRPI0417621A (pt) * 2003-12-17 2007-04-10 Pfizer Prod Inc terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
AU2005274972A1 (en) 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2006043655A1 (ja) 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. 吸入用医薬組成物
AU2005299473B2 (en) * 2004-10-26 2012-06-28 Allergan, Inc. Therapeutic and delivery methods of prostaglandin EP4 agonists
WO2006052630A1 (en) * 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
WO2006052893A2 (en) 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
AU2006209543B2 (en) * 2005-01-27 2009-04-30 Asahi Kasei Pharma Corporation Six-membered heterocyclic compound and the use thereof
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
JP5254007B2 (ja) * 2005-05-06 2013-08-07 アラーガン インコーポレイテッド 置換β−ラクタム及び医薬におけるその使用
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
EP2548559A1 (de) 2006-12-18 2013-01-23 Allergan, Inc. Verfahren und Zusammensetzungen zur Behandlung von Magendarm-Erkrankungen
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
ES2395875T3 (es) * 2007-05-23 2013-02-15 Allergan, Inc. Lactamas cíclicas para el tratamiento del glaucoma o de la presión intraocular elevada
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
JP5536773B2 (ja) * 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
KR20120093955A (ko) 2009-10-14 2012-08-23 젬머스 파마 인코포레이티드 바이러스 감염에 대한 병용 요법 치료
WO2011111714A1 (ja) * 2010-03-08 2011-09-15 科研製薬株式会社 新規なep4アゴニスト
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (de) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Verfahren zur Synthese von Beta-Aminosäuren und Derivaten daraus
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (de) 2011-02-23 2014-01-01 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (de) 2012-02-16 2016-11-02 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
EP2814482A1 (de) 2012-02-16 2014-12-24 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
CA2879506C (en) 2012-07-19 2020-10-27 Cayman Chemical Company, Inc. Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CA2903314C (en) 2013-03-15 2023-02-14 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
EA201591793A1 (ru) * 2013-03-15 2016-01-29 Кайман Кемикал Компани, Инк. Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
EP3021879A2 (de) 2013-07-19 2016-05-25 Cayman Chemical Company, Incorporated Verfahren, systeme und zusammensetzungen zur förderung der knochenwachstums
IL280864B2 (en) 2013-08-09 2024-03-01 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
KR20170010059A (ko) 2014-06-06 2017-01-25 알러간, 인코포레이티드 치료적 화합물로서 신규한 ep4 작용제
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
JP7174982B2 (ja) 2015-06-12 2022-11-18 サイモン フレイザー ユニヴァーシティー アミド連結ep4アゴニスト-ビスホスホネート化合物およびその使用
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
EP3733665B1 (de) * 2017-12-25 2022-09-28 Asahi Kasei Pharma Corporation 2-oxo-1,3,4-thiadiazinan-3-yl-teil enthaltende verbindungen mit ep4-rezeptor-agonistischer aktivität
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
CA1077948A (en) * 1976-08-06 1980-05-20 Albin J. Nelson 1,-5 disubstituted-2-pyrrolidones and processes for their production
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (de) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
TW420669B (en) 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
CA2346038A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
AU1293101A (en) * 1999-12-22 2001-07-03 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
DK1132086T3 (da) * 2000-01-31 2006-08-28 Pfizer Prod Inc Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
CA2429850C (en) * 2000-11-27 2008-12-30 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
DK1339678T3 (da) 2008-02-04
PE20020637A1 (es) 2002-07-18
CY1106976T1 (el) 2012-09-26
IS6775A (is) 2003-04-10
ECSP034623A (es) 2003-07-25
TNSN01166A1 (fr) 2005-11-10
US20040259921A1 (en) 2004-12-23
CZ20031257A3 (cs) 2004-04-14
CA2429850C (en) 2008-12-30
HUP0400807A2 (hu) 2004-07-28
AR035074A1 (es) 2004-04-14
US7192979B2 (en) 2007-03-20
JP2007197467A (ja) 2007-08-09
ES2291361T3 (es) 2008-03-01
BG107697A (en) 2004-01-30
EP1339678A2 (de) 2003-09-03
UY27038A1 (es) 2002-07-31
NO20032360L (no) 2003-07-23
PA8533901A1 (es) 2002-11-28
CN1476429A (zh) 2004-02-18
HN2001000266A (es) 2002-01-30
TW200424170A (en) 2004-11-16
US20020065308A1 (en) 2002-05-30
MA26961A1 (fr) 2004-12-20
EP1339678B1 (de) 2007-09-26
US6747054B2 (en) 2004-06-08
SV2003000746A (es) 2003-01-13
WO2002042268A3 (en) 2002-07-25
SI1339678T1 (sl) 2007-12-31
NO20032360D0 (no) 2003-05-26
NZ525164A (en) 2005-04-29
DE60130675T2 (de) 2008-01-24
GT200100238AA (es) 2004-05-12
BR0115687A (pt) 2003-09-09
PT1339678E (pt) 2007-11-30
ATE374182T1 (de) 2007-10-15
WO2002042268A2 (en) 2002-05-30
MXPA03004623A (es) 2003-09-05
ZA200302803B (en) 2004-04-13
EA200300379A1 (ru) 2003-08-28
IL155368A0 (en) 2003-11-23
JP2004521869A (ja) 2004-07-22
CA2429850A1 (en) 2002-05-30
SK5562003A3 (en) 2004-08-03
JP3984164B2 (ja) 2007-10-03
GT200100238A (es) 2002-06-26
PL362030A1 (en) 2004-10-18
AU2002210848A1 (en) 2002-06-03
US20030149086A1 (en) 2003-08-07
OA12533A (en) 2006-06-05
EE200300246A (et) 2003-10-15
US6552067B2 (en) 2003-04-22
KR20030053063A (ko) 2003-06-27

Similar Documents

Publication Publication Date Title
ATE374182T1 (de) Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
ATE250575T1 (de) Ep4 rezeptor selektive agonisten zur behandlung der osteoporose
ATE266655T1 (de) Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
ATE312117T1 (de) Verbindungen für die behandlung von ischämie
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE50011178D1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
DE60127712D1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
DE60125597D1 (de) Vorrichtung für die Dienstleistungsvermittlung
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
DE60006363D1 (de) Aminoacylaroylpyrrole für die behandlung des neuropathischen schmerzes
ATE357441T1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol- derivative für die behandlung von migräne
IT1316554B1 (it) Dispositivo per il trattamento di rifiuti umidi.
ATE271946T1 (de) Ausziehvorrichtung für pfannenspülsteine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee